Loading
LifeStance Health Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Burdick Kenneth A, was filed 12 Aug 2025.
Insider Decl.
324
Thresholds
n/a
Buy Volume
€427,132
5 ops. · all time
Sell Volume
€1B
126 ops. · all time
Who traded when
BuySaleRobert Bessler18 sales
Kenneth A. Burdick5 buys1 sale
TPG GP A, LLC4 sales
Miller Lisa K3 sales
Black Darren M.2 sales
Pantaleoni Pablo2 sales
+7 other insiders
Since the insiders bought
- +136.4%Entry US$5.17 · Close at T+365 US$12.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate LifeStance Health Group, Inc. Buy (bullish), based on 10 analysts. Average price target: US$14.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,613 of 26,248 companies
37.5
score / 100
Value42
Quality33
FCF yld2.3%
Earn yld0.2%
EV/EBITDA·
ROE3.4%
Gross mgn32%
Net mgn0.7%
Debt/EBITDA6.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.33
Analyst consensus
10 analystsBuy
US$12.00Target US$14.40(+17%)US$18.00
Income statement
RevenueUS$1.4B
Gross profitUS$461.1M32% margin
EBITDAUS$78.8M6% margin
Net incomeUS$9.7M3.2% margin
Valuation
PER (trailing)94.8x
PER (forward)28.6x
P/Book3.2x
Beta1.24
Balance sheet & cash
Market capUS$4.7B
Total debtUS$474.5M
Free Cash FlowUS$110M
Debt / Equity32%
Profitability & ownership
ROE3.4%
ROA2.3%
% insiders3.1%
% institutions91.3%
Last declaration on 24 September 2026
Declarations324 total
150,000 shares0Common StockSEC:0001193125-26-401078:0
150,000 shares0Common StockSEC:0001193125-26-401078:1
150,000 shares0Common StockSEC:0001193125-26-401078:2
150,000 shares0Common StockSEC:0001193125-26-401078:3
18,409,705 shares@ US$12.294.89% mcap27.2% of flowCommon StockSEC:0001999371-26-020559:0
42,067 shares@ US$12.870.012% mcap52.9% of flowCommon StockSEC:0001193125-26-383783:0
150,000 shares0Common StockSEC:0001193125-26-383785:0
8,156 shares@ US$12.160.0021% mcap15.1% of flowCommon StockSEC:0001193125-26-368927:0
7,500 shares@ US$12.680.0021% mcap100.0% of flowCommon StockSEC:0001193125-26-355681:0
7,500 shares@ US$12.68250.0020% mcap27.5% of flowCommonSEC144:0001959173-26-006038
20,441 shares@ US$12.230.0054% mcap72.5% of flowCommonSEC144:0001959173-26-005973
500,000 shares@ US$11.510.13% mcap34.5% of flowCommon StockSEC:0001193125-26-349559:0
13,643,207 shares@ US$10.623.17% mcap24.0% of flowCommon StockSEC:0001999371-26-017719:0
500,000 shares@ US$11.51350.13% mcap34.5% of flowCommonSEC144:0001959173-26-005911
1,088,162 shares@ US$10.620.25% mcap100.0% of flowCommon StockSEC144:0001634426-26-000003
12,165 shares@ US$10.620.0028% mcap100.0% of flowCommon StockSEC144:0001654074-26-000003
1,626 shares@ US$10.620.0004% mcap100.0% of flowCommon StockSEC144:0001660981-26-000002
1,273 shares@ US$10.620.0003% mcap100.0% of flowCommon StockSEC144:0001846709-26-000003
44,394 shares@ US$10.850.011% mcap47.1% of flowCommonSEC144:0001959173-26-005817
47,912 shares@ US$10.850.011% mcap38.1% of flowCommonSEC144:0001959173-26-005821
13,643,207 shares@ US$10.843.24% mcap100.0% of flowCommon Stock, par value $0.01 per shareSEC144:0001999371-26-017532
1,742,770 shares@ US$10.620.40% mcap43.6% of flowCommon StockSEC144:0001634415-26-000002
45,495 shares0Common StockSEC:0001193125-26-303501:0
17,746 shares0Common StockSEC:0001193125-26-297810:0
17,746 shares0Common StockSEC:0001193125-26-297802:0
25 of 324 declarations
About LifeStance Health Group, Inc.
Sales by TPG GP A, LLC dominate the LifeStance Health Group, Inc. record: EUR 194,737,922 on September 11, 2026, EUR 193,278,857 on May 12, 2026 and EUR 125,374,066 on August 10, 2026. The 128 sales total EUR 1.12 billion, with a median of EUR 268,653.
There are 5 purchases, worth EUR 427,132 (median EUR 72,915), or 4% of open-market trades. The three largest are all by Kenneth A. Burdick, Director, who bought EUR 171,280 and EUR 171,276 on August 8, 2025, then EUR 72,915 on August 11, 2025. Burdick has 25 filings, 5 purchases and 2 sales among them.
Read moreShow less
Ann Varanakis, Chief People Officer, and Kevin Michael Mullins, Chief Development Officer, are level at the top of the filers, with 27 filings each; Mullins has 23 sales. David Bourdon, Chief Executive Officer, has signed 25, one of them a sale.
The 316 filings, dated from June 9, 2021 to September 22, 2026, include 166 grants. Annual volume goes from 11 in 2021 to 87 in 2026. Over the last twelve months: 102 filings, 27 sales, no purchase. Insiders hold 3.1% of the capital, across 46 filers. The US healthcare and pharma company is listed on Nasdaq and worth USD 4.47 billion.
